Yueran Cui

425 total citations
10 papers, 311 citations indexed

About

Yueran Cui is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yueran Cui has authored 10 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Cellular and Molecular Neuroscience and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yueran Cui's work include Inflammasome and immune disorders (3 papers), interferon and immune responses (2 papers) and Cancer-related molecular mechanisms research (2 papers). Yueran Cui is often cited by papers focused on Inflammasome and immune disorders (3 papers), interferon and immune responses (2 papers) and Cancer-related molecular mechanisms research (2 papers). Yueran Cui collaborates with scholars based in China. Yueran Cui's co-authors include Juan Feng, Zhongqi Bu, Haiyang Yu, Lulu Wen, Fei Liu, Tong Sun, Jing An, Zijian Li, Yanxia Guo and Juan Feng and has published in prestigious journals such as Frontiers in Immunology, Nutrients and Frontiers in Pharmacology.

In The Last Decade

Yueran Cui

9 papers receiving 306 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yueran Cui China 8 199 95 67 48 47 10 311
Xianming Zhang China 10 166 0.8× 65 0.7× 80 1.2× 85 1.8× 44 0.9× 16 350
Zhongqi Bu China 7 262 1.3× 178 1.9× 56 0.8× 50 1.0× 25 0.5× 8 389
Yongfei Dong China 10 188 0.9× 122 1.3× 64 1.0× 25 0.5× 32 0.7× 24 325
Xiaoxue Xu China 10 226 1.1× 98 1.0× 27 0.4× 21 0.4× 77 1.6× 21 369
Shu Du China 10 197 1.0× 90 0.9× 57 0.9× 13 0.3× 38 0.8× 13 355
Wenqian Huang China 7 125 0.6× 50 0.5× 112 1.7× 35 0.7× 74 1.6× 14 337
Zongze He China 12 292 1.5× 232 2.4× 38 0.6× 33 0.7× 34 0.7× 21 459
Guozuo Wang China 6 158 0.8× 128 1.3× 82 1.2× 125 2.6× 17 0.4× 10 315
Mingze Chang China 11 135 0.7× 43 0.5× 51 0.8× 19 0.4× 21 0.4× 20 264
Qiongxiu Zhou China 10 219 1.1× 28 0.3× 90 1.3× 22 0.5× 65 1.4× 26 423

Countries citing papers authored by Yueran Cui

Since Specialization
Citations

This map shows the geographic impact of Yueran Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yueran Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yueran Cui more than expected).

Fields of papers citing papers by Yueran Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yueran Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yueran Cui. The network helps show where Yueran Cui may publish in the future.

Co-authorship network of co-authors of Yueran Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Yueran Cui. A scholar is included among the top collaborators of Yueran Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yueran Cui. Yueran Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
2.
Yan, Lili, Yueran Cui, & Juan Feng. (2023). Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers. Frontiers in Immunology. 14. 1292022–1292022. 8 indexed citations
3.
Cui, Yueran, et al.. (2022). Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics. Frontiers in Molecular Neuroscience. 15. 894298–894298. 49 indexed citations
4.
Feng, Juan, et al.. (2022). Emodin attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis. Neural Regeneration Research. 18(7). 1535–1535. 20 indexed citations
5.
Cui, Yueran, et al.. (2022). The therapeutic potential of triptolide and celastrol in neurological diseases. Frontiers in Pharmacology. 13. 1024955–1024955. 17 indexed citations
6.
Wang, Zhonglei, Yueran Cui, Lulu Wen, et al.. (2022). Dietary Restriction against Parkinson’s Disease: What We Know So Far. Nutrients. 14(19). 4108–4108. 1 indexed citations
7.
Bu, Zhongqi, Haiyang Yu, Jue Wang, et al.. (2021). Emerging Role of Ferroptosis in the Pathogenesis of Ischemic Stroke: A New Therapeutic Target?. ASN NEURO. 13(1). 3771908417–3771908417. 58 indexed citations
8.
Liu, Yongchao, et al.. (2021). Cerebrospinal fluid cells immune landscape in multiple sclerosis. Journal of Translational Medicine. 19(1). 125–125. 16 indexed citations
9.
Li, Zijian, Yueran Cui, Juan Feng, & Yanxia Guo. (2020). Identifying the pattern of immune related cells and genes in the peripheral blood of ischemic stroke. Journal of Translational Medicine. 18(1). 296–296. 39 indexed citations
10.
Yu, Haiyang, Tong Sun, Jing An, et al.. (2020). Potential Roles of Exosomes in Parkinson’s Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. Frontiers in Cell and Developmental Biology. 8. 86–86. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026